Data / Form D filings / Avilar Therapeutics, Inc.
Avilar Therapeutics, Inc.: Form D filings
Avilar Therapeutics, Inc., a pharmaceuticals company in Waltham, MA, filed 2 Form D notices with the SEC between 2020 and 2023. The latest, on February 13, 2023, reports $75.3 million sold of a $75.3 million offering to 5 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 400 TOTTEN POND ROAD, SUITE 110, Waltham, MA, 02451
- Phone
- (617) 475-8493
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- Massachusetts
- Year incorporated
- 2020
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1836740
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Feb 13, 2023 | Amendment | $75,276,164 | $75,276,164 | 5 | Dec 14, 2020 | sec.gov | |
| Dec 17, 2020 | New notice | $60,000,000 | $20,276,164 | $39,723,836 | 3 | Dec 14, 2020 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| THERESA CAMERON | Director | |
| PAULINA HILL | Director | |
| MARTIN FREED | Director | |
| STEPHANIE TOZZO | Executive Officer | |
| PHIL GRAHAM | Executive Officer | |
| MILIND DESHPANDE | Director | |
| DAVID NEAFUS | Executive Officer | |
| DANIEL GRAU | Executive Officer, Director | |
| ADAM MUZIKANT | Executive Officer | |
| JOSHUA RESNICK | Director |
Other pharmaceuticals companies in Massachusetts that filed recently
- Land Therapeutics Inc. $17.5 million · Oct 21, 2026
- Crosslink Therapeutics Inc. $5.5 million · Oct 20, 2026
- Sentonix, Inc. $12.7 million · Aug 20, 2026
Every Form D from the week of Feb 13, 2023 · All recent filings in Massachusetts · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what Avilar Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.